Skip to main content
SpringerLink
Log in

Atezolizumab not cost effective in advanced NSCLC

  • Clinical study
  • Published:
PharmacoEconomics & Outcomes News

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Notes

  1. 2018 US dollars

  2. epidermal growth factor receptor

  3. anaplastic lymphoma kinase

Reference

  • Lin S, et al. Cost-effectiveness of atezolizumab plus chemotherapy for advanced non-small-cell lung cancer. International Journal of Clinical Pharmacy : 11 Jun 2020. Available from: URL: http://doi.org/10.1007/s11096-020-01076-3

Download references

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Atezolizumab not cost effective in advanced NSCLC. PharmacoEcon Outcomes News 856, 5 (2020). https://doi.org/10.1007/s40274-020-6905-3

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s40274-020-6905-3

Search

Navigation